178 related articles for article (PubMed ID: 25326838)
1. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014; 143 Suppl 2():12-7. PubMed ID: 25326838
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
[TBL] [Abstract][Full Text] [Related]
3. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
5. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
6. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
7. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based therapies, glucometabolic health and endovascular inflammation.
Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.
Cho YM; Wideman RD; Kieffer TJ
Endocrinol Metab (Seoul); 2013 Dec; 28(4):262-74. PubMed ID: 24396690
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
11. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
12. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
[TBL] [Abstract][Full Text] [Related]
13. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
14. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli FS; Shannon RP
J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
[TBL] [Abstract][Full Text] [Related]
17. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.
Madsbad S
Eur J Intern Med; 2012 Mar; 23(2):132-6. PubMed ID: 22284242
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
Scheen AJ
Ann Endocrinol (Paris); 2013 Dec; 74(5-6):515-22. PubMed ID: 23570814
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
